1 completed, 1 not yet recruiting. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Pemetrexed (1): new trials by email Literature Review of Pemetrexed (1) trials Research Report on Pemetrexed (1)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion) - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Henlius Biotech | 1438 | 2026-11-30 | 2026-10-08 |
| Intrathecal Pemetrexed for Leptomeningeal Metastasis Pemetrexed (1), Pemetrexed (2), Folic Acid - Leptomeningeal Metastases | Phase 1 / Phase 2 | Completed | The First Hospital of Jilin University | 34 | 2022-02-21 | 2025-05-04 |
Carcinoma, Non-Small-Cell Lung (1) · Meningeal Carcinomatosis (1)
Shanghai Henlius Biotech (1) · The First Hospital of Jilin University (1)
China (2)
Zhenyu Pan (1)